Diss. (sammanfattning) Uppsala : Univ., 2001. / Härtill 4 uppsatser.

Diss. (sammanfattning) Stockholm : Karol. inst., 2001. / Härtill 7 uppsatser.

Diss. (sammanfattning) Stockholm : Karol. inst., 2000. / Härtill 5 uppsatser.

submitted by Chair Siu Fan. / Thesis (M.Sc.)--Chinese University of Hong Kong, 1998. / Includes bibliographical references (leaves 75-83). / Chapter 1 --- INTRODUCTION --- p.1 / Chapter 2 --- LITERATIRE REVIEW --- p.3 / Chapter 2.1 --- Causes and clinical syndromes in MPS --- p.3 / Chapter 2.1.1 --- MPS --- p.4 / Chapter 2.1.2 --- Classification of MPS --- p.4 / Chapter 2.1.2.1 --- MPS I (Hurler's syndrome) --- p.5 / Chapter 2.1.2.2 --- MPS IS (Scheie syndrome) --- p.5 / Chapter 2 .1.2.3 --- MPS II (Hunter's disease) --- p.6 / Chapter 2.1.2.4 --- MPS Type III (The Sanfilippo diseases) --- p.6 / Chapter 2.1.2.5 --- MPS Type IV (Morquio's disease) --- p.6 / Chapter 2.1.2.6 --- MPS Type VI (Maroteaux 一 Lamy syndrome) --- p.7 / Chapter 2.1.2.7 --- MPS Type VII (Sly syndrome) --- p.8 / Chapter 2.1.3 --- Treatment and prospects for MPS --- p.8 / Chapter 2.1.3.1 --- To manage the handicaps and disabilities --- p.8 / Chapter 2.1.3.2 --- Enzyme replacement --- p.9 / Chapter 2.1.3.3 --- Bone marrow transplantation --- p.10 / Chapter 2.2 --- Basic aspects of GAG --- p.10 / Chapter 2.2.1 --- Distributions of GAG --- p.12 / Chapter 2.2.2 --- Functions and Roles of GAG --- p.12 / Chapter 2.2.3 --- Stepwise degradation of GAGs --- p.12 / Chapter 2.2.4 --- Source of urinary GAG --- p.13 / Chapter 2.2.5 --- Common features of GAGS --- p.14 / Chapter 2.2.6 --- Factors affecting the excretion pattern ot GAG --- p.16 / Chapter 2.3 --- Methods for MPS Diagnosis --- p.16 / Chapter 2.3.1 --- Qualitative urine methods for screening and typing --- p.16 / Chapter 2.3.1.1 --- Spot tests --- p.16 / Chapter 2.3.1.2 --- Precipitation methods --- p.16 / Chapter 2.3.1.3 --- One-dimensional electrophoresis --- p.17 / Chapter 2.3.1.4 --- Two-dimensional electrophoresis --- p.17 / Chapter 2.3.1.5 --- Thin layer chromatography --- p.17 / Chapter 2.3.2 --- Quantitative methods for urinary GAG --- p.17 / Chapter 2.3.2.1 --- Measurement of hexuronic acid --- p.18 / Chapter 2.3.2.2 --- HPLC or Column chromatography --- p.18 / Chapter 2.3.2.3 --- Dye-binding methods --- p.19 / Chapter 2.3.3 --- Cytological studies --- p.19 / Chapter 2.3.4 --- Tissue culture --- p.20 / Chapter 2.3.5 --- Tissue biopsy --- p.20 / Chapter 2.3.6 --- Prenatal diagnosis of the MPS --- p.21 / Chapter 2.4 --- Bacterial GAG hydrolytic enzymes --- p.23 / Chapter 2.5 --- Summary of Literature Review --- p.25 / Chapter 3. --- AIMS OF STUDY --- p.26 / Chapter 4. --- MATERIALS AND METHODS --- p.26 / Chapter 4.1 --- Sample collection --- p.26 / Chapter 4.2 --- Materials &-Equipment --- p.26 / Chapter 4.3 --- Preparation of Reagents and Standards --- p.27 / Chapter 4.3.1 --- Stock DMB reagent solutions --- p.27 / Chapter 4.3.2 --- Working DMB solution --- p.27 / Chapter 4.3.3 --- GAG standards --- p.27 / Chapter 4.3.4 --- Reagents for electrophoresis --- p.27 / Chapter 4.3.4.1 --- 0.1M barium acetate solution --- p.27 / Chapter 4.3.4.2 --- 15% ethanolic barium acetate --- p.28 / Chapter 4.3.4.3 --- 50% ethanolic barium acetate --- p.28 / Chapter 4.3.4.4 --- Alcian blue working solution --- p.28 / Chapter 4.3.4.5 --- 0.1M Tris Buffer --- p.28 / Chapter 4.3.4.6 --- CTB Tris solution --- p.28 / Chapter 4.3.4.7 --- 2.0M lithium chloride --- p.28 / Chapter 4.3.5 --- Reagents for enzymatic degradation --- p.28 / Chapter 4.3.5.1 --- Reconstitution of CSE enzyme --- p.28 / Chapter 4.3.5.2 --- Reconstitution of DSE enzyme --- p.29 / Chapter 4.3.5.3 --- Reconstitution ofHSE I enzyme --- p.29 / Chapter 4.4 --- Methods --- p.31 / Chapter 4.4.1 --- Cobas Bio DMB method --- p.31 / Chapter 4.4.2 --- Cobas Fara DMB method --- p.31 / Chapter 4.4.3 --- Evaluation of methods --- p.31 / Chapter 4.4.3.1 --- To study the matrix effect --- p.31 / Chapter 4.4.3.2 --- Calibration --- p.31 / Chapter 4.4.3.3 --- Precision performance --- p.34 / Chapter 4.4.3.4 --- Linearity check --- p.34 / Chapter 4.4.3.5 --- Detection Limit --- p.34 / Chapter 4.4.3.6 --- Recovery study --- p.35 / Chapter 4.4.3.7 --- Correlation with Cobas Bio to develop the reference range --- p.35 / Chapter 4.4.4 --- Electrophoresis method --- p.36 / Chapter 4.4.4.1 --- Sample preparation --- p.36 / Chapter 4.4.4.2 --- Electrophoresis procedure --- p.36 / Chapter 4.4.5 --- Enzymatic degradation method --- p.37 / Chapter 4.4.5.1 --- Digestion of GAG in aqueous and urine matrix --- p.37 / Chapter 4.4.5.2 --- To optimize the amount of enzyme used to degrade GAG --- p.38 / Chapter 4.4.5.3 --- To study the specificity of GAG degrading enzyme --- p.39 / Chapter 4.4.5.4 --- To study the interaction of GAG --- p.40 / Chapter 4.4.5.5 --- To study the stability of enzyme CSE and DSE --- p.40 / Chapter 4.4.5.6 --- Study MPS patient sample --- p.41 / Chapter 5 --- Results --- p.42 / Chapter 5.1 --- Performance characteristics of the DMB method --- p.42 / Chapter 5.1.1 --- Matrix effect --- p.42 / Chapter 5.1.2 --- Calibration --- p.42 / Chapter 5.1.3 --- Precision performance --- p.42 / Chapter 5.1.4 --- Linearity Range --- p.42 / Chapter 5.1.5 --- Detection limit --- p.42 / Chapter 5.1.6 --- Recovery --- p.47 / Chapter 5.1.7 --- Correlation of Cobas Fara with Cobas Bio --- p.47 / Chapter 5.2 --- Results of GAG enzymatic degradation --- p.50 / Chapter 5.2.2 --- To optimise the amount of enzyme for GAG degradation --- p.57 / Chapter 5.2.3 --- The specificity of GAG degrading enzymes --- p.57 / Chapter 5.2.4 --- The interaction of GAG --- p.57 / Chapter 5.2.5 --- The stability of enzymes --- p.57 / Chapter 5.2.6 --- MPS patient study --- p.57 / Chapter 5.2.6.1 --- Type I/II/VI/VII --- p.57 / Chapter 5.2.6.2 --- MPS Type III patient 1 --- p.64 / Chapter 5.2.6.3 --- MPS Type IIIC patient 2 --- p.64 / Chapter 6. --- DISCUSSION --- p.67 / Chapter 6.1 --- Automated DMB method on Cobas Fara --- p.67 / Chapter 6 2 --- GAG specific degradation enzymes --- p.70 / Chapter 7. --- CONCLUSION & SUGGESTION FOR FUTURE STUDIES --- p.73 / Chapter 8. --- REFERENCES --- p.75

by Shen Tai. / Thesis (M.Phil.)--Chinese University of Hong Kong, 1997. / Includes bibliographical references (leaves 84-92). / Chapter CHAPTER1 --- INTRODUCTION --- p.2 / Chapter CHAPTER2 --- LITERATURE REVIEW / Chapter 2.1 --- Fibronectin --- p.4 / Chapter 2.1a --- Functions and basic molecular structure --- p.4 / Chapter 2.1b --- Polymorphism and alternative splicing --- p.5 / Chapter 2.1c --- Primary classification --- p.6 / Chapter 2.2 --- Oncofetal fibronectin --- p.7 / Chapter 2.2a --- Introduction --- p.7 / Chapter 2.2b --- Recognition by FDC-6 monoclonal antibody --- p.7 / Chapter 2.2c --- Specificity of FDC-6 antibody --- p.8 / Chapter 2.2d --- Glycosylation of fetal fibronectin molecule --- p.9 / Chapter 2.2e --- Fibronectin and human pregnancy --- p.9 / Chapter 2.2f --- Regulation of fetal fibronectin synthesis --- p.11 / Chapter 2.2g. --- Possible mechanism of fetal fibronectin release --- p.12 / Chapter 2.3 --- The uterine cervix in human labour --- p.13 / Chapter 2.3a --- Introduction --- p.14 / Chapter 2.3b --- Physiological cervical ripening --- p.14 / Chapter 2.3c --- Role of prostaglandins --- p.16 / Chapter 2.3d --- Fibronectin and degradation of cervical matrix --- p.16 / Chapter 2.4 --- Evaluation of cervical status --- p.17 / Chapter 2.4a --- Bishop score --- p.17 / Chapter 2.4b --- Intravaginal ultrasound evaluation of cervix --- p.18 / Chapter 2.4c --- Fibronectin as a tool for evaluation of cervical status --- p.19 / Chapter 2.5 --- Pre-induction cervical ripening with PGE2 --- p.20 / Chapter 2.5a --- Introduction --- p.20 / Chapter 2.5b --- Route of delivery --- p.21 / Chapter 2.5c --- Indications for cervical ripening with prostaglandins --- p.21 / Chapter 2.5d --- Possible Mechanism --- p.22 / Chapter 2.5e --- PGE2 effectiveness and potential risks --- p.23 / Chapter 2.5f --- Other cervical ripening techniques and agents --- p.25 / Chapter 2.5g --- Prediction for outcomes of induction and pre- induction cervical ripening with PGE2 --- p.26 / Chapter 2.6 --- Application of fibronectin in Obstetrics --- p.29 / Chapter 2.6a --- Prediction of preterm delivery --- p.29 / Chapter 2.6b --- Evaluation of cervical status --- p.31 / Chapter 2.6c --- Prediction of prolonged pregnancy --- p.32 / Chapter 2.6d --- Prediction for outcomes of induced labor --- p.32 / Chapter CHAPTER3 --- METHODOLOGY / Chapter 3.1 --- Introduction --- p.36 / Chapter 3.2. --- Study population and recruitment --- p.36 / Chapter 3.2a --- Inclusive criterion --- p.36 / Chapter 3.2b --- Exclusive criterion --- p.36 / Chapter 3 3 --- Measurement of Fetal Fibronectin --- p.38 / Chapter 3.3.1 --- Fetal Fibronectin Membrane Immunoassay --- p.39 / Chapter 3.3.1a --- Principle of the test --- p.39 / Chapter 3.3.1b --- Reagent and materials --- p.39 / Chapter 3.3.1c --- Specimen collection --- p.40 / Chapter 3.3.1d --- Assay procedure and interpretation of results --- p.40 / Chapter 3.3.2 --- Fetal Fibronectin Enzyme Immunoassay --- p.40 / Chapter 3.3.2a --- Principle of the test --- p.40 / Chapter 3.3.2b --- Materials --- p.41 / Chapter 3.3.2c --- Specimen collection --- p.42 / Chapter 3.3.2d --- Assay procedure and interpretation of results --- p.43 / Chapter 3.4 --- Cervical status determination --- p.44 / Chapter Chapter4 --- RESULT --- p.47 / Chapter Chapter5 --- DISCUSSION --- p.80 / REFERENCES --- p.83

The increasing incidence of disseminated (invasive) candidiasis is probably attributable to iatrogenic factors and to improved pre and postmortem evaluation. Premortem diagnosis of such infections have seldom been made early enough for successful treatment. In order to increase the likelihood of successful antifungal chemotherapy, rapid diagnosis of such infections is vital. However, present diagnostic procedures for invasive candidiasis are insensitive and often do not reliably differentiate superficial from invasive infections. This study was undertaken to produce DNA probes and to optimize conditions for rapid and efficient detection of Candida DNA. Seven random Candida albicans DNA fragments (2-7 kbp) were cloned into plasmid pACYC 184. These recombinant plasmids were labeled with either ³²p or biotin and used as probes. Two of the four recombinant plasmids tested were genus specific. The other two were slightly cross reactive with other yeasts (Saccharomyces cerevisiae and Hansenula anomala). Probes labeled with ³²p were twice as sensitive as the biotin probes. One ³²p labelled recombinant (#66) detected 7 Pg of target DNA , which corresponds to approximately 2 X 10⁵ C.albicans cells. With refined simple DNA extraction procedures for C.albicans (in serum), these recombinant probes could possibly be suitable for clinical application. / Medicine, Faculty of / Pathology and Laboratory Medicine, Department of / Graduate

M.A.

Hui, Lai Shan. / Thesis (M.Sc.)--Chinese University of Hong Kong, 1988. / Bibliography: leaves 83-87.

by Ye Jian. / Abstract in English and Chinese. / Thesis (M.Phil.)--Chinese University of Hong Kong, 1993. / Includes bibliographical references (leaves [140-147]). / ABSTRACT --- p.i / ACKNOWLEDGEMENTS --- p.v / LIST OF ABBREVIATIONS --- p.vi / TABLE OF CONTENTS / Chapter CHAPTER 1 --- Introduction / Chapter 1.1 --- What is the EBI technique --- p.1-1 / Chapter 1.2 --- Applications of the EBI technique --- p.1-2 / Chapter 1.3 --- The electrical impedance rheopneumography-an overview --- p.1-4 / Chapter 1.4 --- Goal of the work --- p.1-6 / Chapter 1.5 --- Main contributions of the work --- p.1-9 / Chapter 1.6 --- Organization of the thesis --- p.1-9 / Chapter CHAPTER 2 --- Principles of the EBI technique and physiological background of the rheopneumogram / Chapter 2.1 --- Tissue impedance and origins of impedance change --- p.2-1 / Chapter 2.1.1 --- Impedance of living organs --- p.2-1 / Chapter 2.1.2 --- Origins of impedance change --- p.2-2 / Chapter 2.2 --- The data acquisition system (DAS) --- p.2-3 / Chapter 2.2.1 --- Impedance detector --- p.2-3 / Chapter 2.2.2 --- Constant current source and safety consideration --- p.2-4 / Chapter 2.2.3 --- Computer interface --- p.2-5 / Chapter 2.3 --- Electrode systems --- p.2-6 / Chapter 2.3.1 --- Two-/four-electrode systems --- p.2-6 / Chapter 2.3.2 --- Geselowitz lead field theory --- p.2-6 / Chapter 2.3.3 --- Comparisons between the two-/four-electrode systems --- p.2-7 / Chapter 2.4 --- The human cardiovascular system --- p.2-8 / Chapter 2.4.1 --- System operation --- p.2-8 / Chapter 2.4.2 --- Pulmonary hemodynamics --- p.2-9 / Chapter 2.5 --- Physiological background of EIR waveform --- p.2-12 / Chapter 2.6 --- EIR wave morphology and pathological factors --- p.2-13 / Chapter 2.6.1 --- Variations in the a-wave --- p.2-13 / Chapter 2.6.2 --- Variations in the Z-wave --- p.2-14 / Chapter 2.6.3 --- Variations in the C-wave --- p.2-14 / Chapter CHAPTER 3 --- THE COMPOSITION OF IMPEDANCE SIGNAL / Chapter 3.1 --- Introduction --- p.3-1 / Chapter 3.1.1 --- Origins of the TIS --- p.3-1 / Chapter 3.1.2 --- EIR measurement and electrode position --- p.3-2 / Chapter 3.1.3 --- Optimal EIR measurement --- p.3-3 / Chapter 3.2 --- Current path in an inhomogeneous medium --- p.3-4 / Chapter 3.3 --- Numerical model --- p.3-5 / Chapter 3.3.1 --- 2D Model --- p.3-5 / Chapter 3.3.2 --- Tissue resistivity --- p.3-6 / Chapter 3.4 --- Calculation of the potential distribution --- p.3-7 / Chapter 3.5 --- Results --- p.3-9 / Chapter 3.5.1 --- Computer simulations --- p.3-9 / Chapter 3.5.2 --- Experimental results --- p.3-13 / Chapter 3.6 --- Discussions --- p.3-14 / Chapter 3.7 --- Conclusion --- p.3-16 / Chapter 3.8 --- Note on publications --- p.3-17 / Chapter CHAPTER 4 --- ON-LINE RESPIRATORY ARTEFACT REMOVAL VIA ADAPTIVE TECHNIQUE / Chapter 4.1 --- Introduction --- p.4-1 / Chapter 4.2 --- Analysis of the TIS --- p.4-3 / Chapter 4.3 --- Modified adaptive noise canceller --- p.4-7 / Chapter 4.3.1 --- Principle of the ANC method --- p.4-8 / Chapter 4.3.2 --- LMS algorithm --- p.4-8 / Chapter 4.3.3 --- MANC method --- p.4-9 / Chapter 4.3.4 --- Results --- p.4-10 / Chapter 4.4 --- Adaptive moving averager --- p.4-15 / Chapter 4.4.1 --- Modified moving averager --- p.4-15 / Chapter 4.4.2 --- Respiratory artefact elimination with adaptive MMA --- p.4-16 / Chapter 4.4.3 --- Performance of the adaptive MMA filter --- p.4-16 / Chapter 4.4.4 --- Results --- p.4-18 / Chapter 4.5 --- Adaptive FIR filter Design --- p.4-22 / Chapter 4.5.1 --- Introduction --- p.4-22 / Chapter 4.5.2 --- Adaptive FIR filter --- p.4-23 / Chapter 4.5.3 --- Results and discussions --- p.4-24 / Chapter 4.6 --- Simultaneously monitoring respiratory and pulmonary circulation- An application of TIS --- p.4-30 / Chapter 4.7 --- Comparisons of the proposed filter schemes --- p.4-33 / Chapter 4.7.1 --- Performance of the filters --- p.4-33 / Chapter 4.7.2 --- Computational complexity and reduced schemes --- p.4-34 / Chapter 4.8 --- Conclusions --- p.4-37 / Chapter 4.9 --- Notes on publications --- p.4-37 / Chapter CHAPTER 5 --- MODELING ANALYSIS OF THE RHEOPNEUMOGRAM / Chapter 5.1 --- Introduction --- p.5-1 / Chapter 5.2 --- Pulmonary circulation modeling --- p.5-2 / Chapter 5.3 --- Model deduction --- p.5-4 / Chapter 5.3.1 --- Pressure-flow in arteries and veins --- p.5-4 / Chapter 5.3.2 --- The two-chamber model and the EIR model --- p.5-5 / Chapter 5.4 --- Parameter estimation --- p.5-8 / Chapter 5.4.1 --- The fitting function and the parameter equations --- p.5-8 / Chapter 5.4.2 --- Curve fitting --- p.5-10 / Chapter 5.4.3 --- Solution of the parameter equations --- p.5-11 / Chapter 5.5 --- Study of the model parameter sensitivity --- p.5-12 / Chapter 5.6 --- Results --- p.5-13 / Chapter 5.7 --- Conclusion --- p.5-17 / Chapter 5.8 --- Notes on publications --- p.5-17 / Chapter CHAPTER 6 --- ANIMAL EXPERIMENTS AND CLINICAL OBSERVATIONS / Chapter 6.1 --- Introduction --- p.6-1 / Chapter 6.2 --- Animal experiments --- p.6-2 / Chapter 6.2.1 --- Methods --- p.6-2 / Chapter 6.2.2 --- Occlusion of the right pulmonary arterial blood flow --- p.6-3 / Chapter 6.2.3 --- Reflection waves in rheopneumogram --- p.6-4 / Chapter 6.3 --- Clinical observations --- p.6-4 / Chapter 6.3.1 --- Mitral valve stenosis --- p.6-5 / Chapter 6.3.2 --- Obstructive emphysema --- p.6-7 / Chapter 6.4 --- Conclusion remarks --- p.6-8 / Chapter 6.5 --- Notes on publications --- p.6-9 / Chapter CHAPTER 7 --- RECAPITULATION AND TOPICS FOR FUTURE INVESTIGATION / Chapter 7.1 --- Recapitulation --- p.7-1 / Chapter 7.2 --- Conclusions --- p.7-3 / Chapter 7.3 --- Topics for future investigation --- p.7-4 / Chapter 7.4 --- Applications of the EIR technique --- p.7-5 / REFERENCES / APPENDICES / Chapter A. --- A circuit diagram of the four-electrode system --- p.A-l / Chapter B. --- NISA/EMAG (A SOFTWARE PACKAGE OF FEM) --- p.A-2 / Chapter C. --- LMS algorithm --- p.A-3 / Chapter D. --- Curve fitting --- p.A-5 / Chapter E. --- List of publications --- p.A-8

Chiu Hoi Shan Clarissa. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2001. / Includes bibliographical references (leaves 110-126). / Abstracts in English and Chinese. / Abstract in English --- p.i / Abstract in Chinese --- p.iii / Acknowledgement --- p.iv / List of Abbreviations --- p.v / List of Tables --- p.vi / List of Figures --- p.viii / Introduction and Objectives / Hepatocellular Carcinoma / Epidemiology --- p.1 / Sex and Age --- p.1 / Geographic distibution --- p.2 / Risk factors of HCC --- p.2 / Mortality from liver cancer --- p.4 / Treatment for HCC --- p.4 / Tumor markers --- p.5 / Alpha-fetoprotein / Structure --- p.5 / Physiological Functions of AFP --- p.7 / Re-expression of AFP in Adult --- p.7 / Re-expression of AFP in HCC --- p.8 / Isoforms of AFP --- p.8 / Specific AFP isoform in HCC --- p.9 / Sialic Acid --- p.11 / Sialyltransferase / "Galβ 1,4GlcnAc α2,6-sialyitransferase" --- p.12 / "Characterization of ST2,6Gal I" --- p.12 / "Expression of ST2,6Gal I" --- p.12 / "General features of ST2,6Gal I Activity" --- p.15 / Relationship Between AFP isoforms and ST2，6Gal in Fetal Mouse Model --- p.15 / "Change in ST2,6GaI I Activity in Transgenic Mouse Models of HCC" --- p.16 / "Study of Activity of ST2,6Gal I in Colon Carcinoma" --- p.16 / Objective of the Project --- p.18 / Chapter Chapter 1 --- Formation of Monosialyated AFP by Hepatoma Cells / Chapter 1.1 --- Introduction --- p.21 / Chapter 1.2 --- Materials and Methods --- p.23 / Chapter 1.3 --- Results / Chapter 1.3.1 --- AFP obtained from cell culture --- p.34 / Chapter 1.3.2 --- IEF for AFP in cell culture medium --- p.34 / Chapter 1.3.3 --- SDS-PAGE analysis of AFP --- p.34 / Chapter 1.3.4 --- Stability of AFP isoforms after secreted to cell culture medium --- p.39 / Chapter 1.3.5 --- Comparison of the AFP isoforms between liver tissues and serum --- p.38 / Chapter 1.4 --- Discussion / Chapter 1.4.1 --- Origin of the extracellular msAFP - in vitro Model --- p.43 / Chapter 1.4.2 --- Origin of circulating msAFP - in vivo Model --- p.44 / Chapter 1.5 --- Conclusion --- p.46 / Chapter Chapter 2 --- "Presence of msAFP in the serum of HCC patient is a Consequence of Decrease in the Activity of ST2, / Chapter 2.1 --- Introduction --- p.47 / Chapter 2.2 --- Materials and Methods --- p.49 / Chapter 2.3 --- Results / Chapter 2.3.1 --- Semi-quantitation of msAFP --- p.61 / Chapter 2.3.2 --- Evaluation of the ST2，6Gal I Assay --- p.65 / Chapter 2.3.3 --- "Measurements and comparisons of the activity of ST2,6Gal I in non-tumor and tumor tissue" --- p.65 / Chapter 2.3.4 --- "Evaluation of the RT-PCR ELISA for semi-quantitation and comparisons of ST2,6Gal I mRNA levels" --- p.75 / Chapter 2.3.5 --- "Semi-quantitation and comparisons of ST2,6Gal I mRNA levels in the non-tumor and tumor tissues" --- p.84 / Chapter 2.3.6 --- Correlations between the markers --- p.87 / Chapter 2.4 --- Discussion / Chapter 2.4.1 --- "Overproduction of AFP, a possible cause for increased msAFP formation" --- p.99 / Chapter 2.4.2 --- "Decrease of ST2,Gal I activity, a possible cause for increased msAFP formation" --- p.100 / Chapter 2.4.3 --- "ST2,6Gal I activity in tumor is not regulated at transcriptional level" --- p.102 / General Discussion / Origin of blood stream msAFP --- p.103 / Physiological Mechanism for the formation of msAFP in HCC --- p.104 / Regulation of ST2，6Gal I activity in HCC --- p.105 / "Comparison between the ST2,6GaI I activities in human HCC and Colon Cancer" --- p.107 / Conclusion and Future studies / Conclusion --- p.108 / Future studies --- p.109 / References --- p.110